TEANECK, N.J. / May 20, 2024 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Stifel Annual Dental and Animal Health (Jaws & Paws) Conference.
Chief Financial Officer, Glenn David along with Larry Miller, Chief Operating Officer and EVP Corporate Strategy, Daniel Bendheim will address financial analysts and investors on Wednesday, May 29, 2024, at 10:20 AM ET at the St. Regis New York.
The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company’s website.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.
Our filings with the Securities and Exchange Commission are available online at www.sec.gov, www.pahc.com or on request from the company.
| Last Trade: | US$26.11 |
| Daily Change: | -0.39 -1.47 |
| Daily Volume: | 350,440 |
| Market Cap: | US$531.860M |
January 23, 2025 August 28, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
